Short, Vanessa L.Hoffman, MatthewMetgud, MrityunjayKavi, AvinashGoudar, Shivaprasad S.Okitawutshu, JeanTshefu, AntoinetteBose, Carl L.Mwenechanya, MusakuChomba, ElwynCarlo, Waldemar A.Figueroa, LesterGarces, AnaKrebs, Nancy F.Jessani, SaleemSaleem, SarahGoldenberg, Robert L.Das, Prabir KumarPatel, ArchanaHibberd, Patricia L.Achieng, EmmahNyongesa, PaulEsamai, FabianBucher, SherriNowak, Kayla J.Goco, NormanNolen, Tracy L.McClure, Elizabeth M.Koso-Thomas, MarionMiodovnik, MenachemDerman, Richard J.2022-08-242022-08-242021Short, V. L., Hoffman, M., Metgud, M., Kavi, A., Goudar, S. S., Okitawutshu, J., Tshefu, A., Bose, C. L., Mwenechanya, M., Chomba, E., Carlo, W. A., Figueroa, L., Garces, A., Krebs, N. F., Jessani, S., Saleem, S., Goldenberg, R. L., Das, P. K., Patel, A., … Derman, R. J. (2021). Safety of daily low-dose aspirin use during pregnancy in low-income and middle-income countries. AJOG Global Reports, 1(1), 100003. https://doi.org/10.1016/j.xagr.2021.10000326665778https://hdl.handle.net/1805/29876BACKGROUND The daily use of low-dose aspirin may be a safe, widely available, and inexpensive intervention for reducing the risk of preterm birth. Data on the potential side effects of low-dose aspirin use during pregnancy in low- and middle-income countries are needed. OBJECTIVE This study aimed to assess differences in unexpected emergency medical visits and potential maternal side effects from a randomized, double-blind, multicountry, placebo-controlled trial of low-dose aspirin use (81 mg daily, from 6 to 36 weeks’ gestation). STUDY DESIGN This study was a secondary analysis of data from the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial, a trial of the Global Network for Women's and Children's Health conducted in India (2 sites), Pakistan, Guatemala, Democratic Republic of the Congo, Kenya, and Zambia. The outcomes for this analysis were unexpected emergency medical visits and the occurrence of the following potential side effects—overall and separately—nausea, vomiting, rash or hives, diarrhea, gastritis, vaginal bleeding, allergic reaction, and any other potential side effects. Analyses were performed overall and by geographic region. RESULTS Between the aspirin (n=5943) and placebo (n=5936) study groups, there was no statistically significant difference in the risk of unexpected emergency medical visits or the risk of any potential side effect (overall). Of the 8 potential side effects assessed, only 1 (rash or hives) presented a different risk by treatment group (4.2% in the aspirin group vs 3.5% in the placebo group; relative risk, 1.20; 95% confidence interval, 1.01–1.43; P=.042). CONCLUSION The daily use of low-dose aspirin seems to be a safe intervention for reducing the risk of preterm birth and well tolerated by nulliparous pregnant women between 6 and 36 weeks’ gestation in low- and middle-income countries.en-USAttribution-NonCommercial-ShareAlike 4.0 Internationallow- and middle-income countrieslow-dose aspirinpreterm birthArticle